Eicosamed

Eicosamed is a clinical-stage biotechnology company dedicated to developing a new class of non-opioid analgesics for the treatment of severe pain and inflammatory diseases. The company's lead candidate, EC5026, is a potent, orally bioavailable small molecule inhibitor of soluble epoxide hydrolase (sEH), an enzyme that regulates naturally occurring anti-inflammatory and analgesic fatty acids. By stabilizing these lipid mediators, Eicosamed aims to provide effective pain relief without the addictive potential or side effects associated with opioids and NSAIDs. Founded on pioneering research from the University of California, Davis, the company is currently advancing its pipeline through clinical trials for neuropathic and inflammatory pain conditions. The firm has received significant backing from the NIH HEAL Initiative to address the ongoing opioid crisis.